Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies. As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors. Epsilogen CEO Tim Wilson said: “We are excited to create […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!